OMRON Healthcare Co., Ltd. announced new initiatives to accelerate its global electrocardiogram (ECG) business strategy, ...

Secures FDA 510(K) Clearance For 12-Lead ECG Synthesis Software Following Successful Appeal. HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through ...

KUWAIT: Dr Mohammed Zubaid, Consultant Cardiologist and Vice President of the Kuwait Heart Association, affirmed that heart failure is a widespread condition, noting that it requires urgent medical ...

HeartBeam’s ECG software duplicates the 12-lead ECG approach undertaken in healthcare settings with electrodes to evaluate ...

HeartBeam's 1st synthesized 12-lead ECG cleared by FDA, enabling cable-free at-home arrhythmia assessment with launch set for 2026.

HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac ...

Unlike any single-lead or 6-lead consumer device, HeartBeam's patented cable-free technology captures the heart's electrical signals in three non-coplanar dimensions and synthesizes them into a ...

LAS CRUCES, NEW MEXICO / ACCESS Newswire / December 2, 2025 / Following CMS’s announcement of the new ACCESS Model (Advancing ...

A screenshot from a video demonstrating how to use the HeartBeam ECG device. HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) ...

Background The cross-sectional association between cerebral tissue oxygen saturation (SctO2) and heart failure (HF) has been previously studied, but the prognostic significance of SctO2 in HF remains ...

Allied Market Research published a report, titled, " Cardiovascular Diagnostic Device Market by Type (Electrocardiogram ...

Faraz Ahmad, MD, and Marie-Noelle Langan, MD, discuss the role of artificial intelligence (AI) for cardiac care within healthcare systems.